ProfileGDS5678 / 1416865_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 31% 42% 34% 31% 30% 35% 45% 32% 31% 28% 41% 31% 31% 38% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7490231
GSM967853U87-EV human glioblastoma xenograft - Control 22.9684142
GSM967854U87-EV human glioblastoma xenograft - Control 32.774134
GSM967855U87-EV human glioblastoma xenograft - Control 42.6469231
GSM967856U87-EV human glioblastoma xenograft - Control 52.6253630
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.8638335
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.1185745
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.7050632
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.6757631
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.6263428
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9410541
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.67531
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.7023931
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8744438